
Innovative Hydrogen Therapy for Fighting Chronic Diseases
Fibrosis
Fibrosis, a hallmark of numerous chronic inflammatory conditions, represents a formidable challenge in modern healthcare due to its pervasive impact on organ function and mortality rates. The pathological process of fibrosis, characterized by the excessive accumulation of extracellular matrix components, is intricately intertwined with chronic inflammation and metabolic imbalances. Formerly perceived as an irreversible cascade, recent scientific endeavors have unveiled the dynamic nature of fibrosis, offering new avenues for therapeutic intervention.
Myofibroblasts, arising from diverse cellular sources, emerge as central players in organ fibrosis, embryonic development, and the stromal response to malignancies. Moreover, the interplay between oxidative stress, inflammation, and immunity shapes the fibrotic milieu, highlighting the multifaceted nature of this pathological process. This evolving comprehension of fibrosis not only enhances the grasp of disease mechanisms but also fosters optimism for innovative treatment modalities aimed at mitigating its devastating consequences.
Recent estimates suggest that fibrotic disease is responsible for almost half of all deaths in Western developed countries.
Fibrosis affects nearly all tissues and organ systems.
Fibrosis is a dynamic process with the potential for reversibility and restoration of near-normal tissue architecture and organ function.
Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including autoimmune diseases, persistent infections, allergic responses, chemotherapy drugs (and some other drugs), radiation, chemical insults and tissue injury (physical or ischemic).
Fibrosis is a pathological feature of most chronic inflammatory autoimmune diseases.
The underlying molecular and cellular events of fibrotic autoimmune diseases share many functional similarities, despite differences in aetiology and clinical evolution.
Most of the current therapeutic agents target the terminal phase of the chronic inflammation of autoimmune diseases and do not address the fundamental problems that are responsible for the initiation and progression of the autoimmune process which often leads to organ fibrosis.
Lately, accumulating studies from human and animal models suggest that the potential to reverse fibrotic changes exists in most organs/ tissues studied, including the liver, lung, kidney, skeletal muscle, heart, and bone marrow.
The time required for the resolution of fibrosis may vary depending on the organ involved, the cause of injury, and host-specific factors such as age, genetic and epigenetic background, immune competence and antioxidants applied.
Hydrogen therapy emerged as a promising antioxidant therapy for treating immune-mediated/ autoimmune diseases. In many inflammatory diseases, inflammation is mainly caused by the over-activation of pro-inflammatory substances of the immune system.